# Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00085345** · PHASE2 · WITHDRAWN · sponsor: **Oncotherapeutics**

## Conditions studied

- Stage II Multiple Myeloma
- Stage III Multiple Myeloma
- Refractory Plasma Cell Neoplasm

## Interventions

- **DRUG:** arsenic trioxide
- **DRUG:** ascorbic acid
- **DRUG:** melphalan
- **PROCEDURE:** chemosensitization/potentiation
- **PROCEDURE:** chemotherapy

## Key facts

- **NCT ID:** NCT00085345
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085345, "Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00085345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*